Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213778 · ClinicalTrials.gov registry record · Phase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
A Phase 3 study of Symptomatic Venous Thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 10
- Study locations
NCT07213778: Recruiting Phase 3 study of Symptomatic Venous Thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals.
NCT07213778 is a Phase 3 study of Symptomatic Venous Thromboembolism (VTE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213778, a Phase 3 study of Symptomatic Venous Thromboembolism (VTE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7508
- DRUG Acetylsalicylic Acid (ASA)
Study Locations (10)
Florida
- Medical Research of Westchester - MPLUS Research Network - Miami
- Phoenix Clinical Research - Tamarac
Texas
- HD Research - Memorial Hermann Village - Houston
- Endeavor Clinical Trials - San Antonio
Colorado
- Sky Ridge Medical Center - Lone Tree
Kansas
- NextStage Clinical Research, St. Francis Medical Park - Wichita
Maryland
- Sinai Hospital of Baltimore, Inc. - Baltimore
New Jersey
- Holy Name Medical Center - Teaneck
Ohio
- Ohio Clinical Trials - Columbus
Washington
- Spokane Joint Replacement Center - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2027-07-16 |
| Phase | Phase 3 |
What NCT07213778 shows while recruiting
NCT07213778 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (159% higher).
The record links to 1 condition, with Symptomatic Venous Thromboembolism (VTE) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07213778 lists 10 locations in 8 states (Florida, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT07213778 about?
NCT07213778 is a clinical study titled "REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants". This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at pr...
What is the current status of trial NCT07213778?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2025-11-24. Estimated completion is 2027-07-16.
What conditions does trial NCT07213778 study?
This clinical trial studies the following conditions: Symptomatic Venous Thromboembolism (VTE).
What interventions are being tested in trial NCT07213778?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG), Acetylsalicylic Acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT07213778?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213778 being conducted?
This trial has 10 study locations across Colorado, Florida, Kansas, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07213778's enrollment target sits among peer trials
2,000 100th of 2000 higher than 1,896 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI